Orla Macdonald
Oxford, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Impact of the COVID-19 pandemic on antidepressant prescribing with a focus on people with learning disability and autism: an interrupted time series analysis in England using OpenSAFELY-TPP.
Journal: BMJ mental health
Published: December 10, 2024
Impact of the COVID-19 pandemic on antipsychotic prescribing in individuals with autism, dementia, learning disability, serious mental illness or living in a care home: a federated analysis of 59 million patients' primary care records in situ using OpenSAFELY.
Journal: BMJ mental health
Published: May 30, 2023
Data-Driven Identification of Unusual Prescribing Behavior: Analysis and Use of an Interactive Data Tool Using 6 Months of Primary Care Data From 6500 Practices in England.
Journal: JMIR medical informatics
Published: November 11, 2022
Changes in medication safety indicators in England throughout the covid-19 pandemic using OpenSAFELY: population based, retrospective cohort study of 57 million patients using federated analytics.
Journal: BMJ medicine
Published: November 03, 2022
Identifying Patterns of Clinical Interest in Clinicians' Treatment Preferences: Hypothesis-free Data Science Approach to Prioritizing Prescribing Outliers for Clinical Review.
Journal: JMIR medical informatics
Published: July 19, 2022
OpenSAFELY NHS Service Restoration Observatory 2: changes in primary care clinical activity in England during the COVID-19 pandemic.
Journal: The British journal of general practice : the journal of the Royal College of General Practitioners
Published: June 08, 2022
COVID-19 and substance use disorders: a review of international guidelines for frontline healthcare workers of addiction services.
Journal: BMC psychiatry
Published: July 19, 2021
How pharmacist prescribers can help meet the mental health consequences of COVID-19.
Journal: Evidence-based mental health
Published: September 28, 2020
A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania.
Journal: Psychopharmacology
Published: June 29, 2020
Last Updated: 09/26/2026